Where Do Subcutaneous Injections Go?

Fluid from a subcutaneous injection lands in the hypodermis, the fatty tissue layer sitting just beneath the skin’s outer layers (the epidermis and dermis) and above the muscle. Once deposited there, it forms a small pool, sometimes called a depot, that gradually disperses through the surrounding fat and connective tissue before being picked up by nearby blood capillaries or lymphatic vessels. How quickly and completely that happens depends on the drug’s molecular size, the anatomy of the injection site, and a handful of patient-specific factors that make this seemingly simple delivery route more variable than most people realize.

What the Subcutaneous Layer Actually Looks Like

The hypodermis is not a uniform sponge. It consists of lobules of fat separated by fibrous walls called septae, which give the tissue a compartmentalized structure. High-resolution ultrasound imaging of the subcutaneous layer shows it as a mix of these fatty lobules and denser connective-tissue dividers.¹ When you push fluid into this space with a needle, it does not simply pool in a neat sphere. The injected liquid has to work its way around and through these fatty compartments and fibrous walls, which is why researchers model the tissue as having directional properties rather than behaving the same in all directions.²

The thickness of this layer varies enormously. It is generally thickest in the abdomen and thinnest at the limbs, and it tends to be thicker in women than in men.³ That thickness matters because if the needle is too long for a particular person’s anatomy, the injection can overshoot the fat layer entirely and land in the muscle beneath it, which changes the drug’s absorption profile.

How Fluid Spreads After the Needle Pulls Out

Micro-CT imaging, which captures the tissue in three dimensions at very fine resolution, has given researchers a detailed look at what happens to injected fluid in the moments after delivery. In one study using high-resolution scans of subcutaneous tissue, the injected volume was the main factor determining how far the fluid spread. Viscosity and injection speed did not significantly change the spatial distribution within the range tested.⁴ In practical terms, a larger injection creates a larger depot, but the tissue’s internal architecture, those septae and fat lobules, shapes where the fluid actually ends up more than how fast you push the plunger.

The tissue is surprisingly accommodating when you inject slowly. In a study using pig models, a 10 mL injection delivered over ten minutes generated lower back pressure than a 1 mL injection pushed in over ten seconds.⁵ Once the injection stops, that pressure falls back to zero within seconds. The tissue is not rigid; it stretches and redistributes the fluid over time. Clinical studies in healthy adults have confirmed that volumes up to 10 mL in the abdomen and 5 mL in the thigh are feasible, with pain peaking during the injection itself and fading within about ten minutes afterward.⁶ Interestingly, in another tolerance study, higher viscosity solutions were actually the best tolerated, and injection volume by itself did not drive perceived pain.⁷

Two Roads Into the Bloodstream

Once the depot sits in the subcutaneous fat, the drug needs to reach the bloodstream to have a systemic effect. There are two main exit routes: blood capillaries and lymphatic vessels. Which route dominates depends heavily on the size of the molecule.

Small molecules pass easily through the walls of blood capillaries and get absorbed directly into the blood. Larger molecules, especially proteins and antibodies, are too big to slip through capillary walls efficiently. Instead, they drain into lymphatic vessels, which are more permeable to large particles, and eventually empty into the bloodstream via the thoracic duct. A landmark study in sheep measured this relationship directly: for a small molecule (molecular weight around 250), only about 4% of the dose traveled through the lymphatic system. As molecular weight climbed, so did lymphatic uptake, reaching about 21% for a molecule around 5,200 in weight, roughly 39% for one around 12,300, and about 60% for interferon alpha-2a at 19,000. The relationship was essentially linear, and molecules above about 16,000 in weight were absorbed primarily through the lymphatics.⁸

This distinction matters practically. Lymphatic flow is slow compared to blood flow, which is one reason large biologic drugs, such as monoclonal antibodies, take days to reach peak blood levels after a subcutaneous injection rather than minutes. Simulation work has confirmed that lymphatic flow rate is the single most influential factor determining how long it takes an antibody to reach peak concentration.⁹ The restricted movement of large antibody molecules through the dense subcutaneous tissue also explains why their overall absorption is incomplete, typically around 50–80% of the injected dose makes it to the bloodstream.¹⁰

Does It Matter Where You Inject?

The abdomen, outer thigh, and upper arm are the three standard subcutaneous injection sites, and patients often wonder whether the choice makes a real difference. The answer depends on what you are injecting. A survey of clinical data across dozens of drug products found that about half of smaller peptide and protein drugs showed absorption that varied by injection site, while about a quarter of larger antibody drugs did. Regional differences in blood flow, lymphatic drainage, and local tissue metabolism all contribute.¹¹

For some drugs, though, the site barely matters. Golimumab, an antibody used for autoimmune conditions, was tested head-to-head at all three sites in healthy men. The overall bioavailability was about 51%, and absorption was similar regardless of whether the injection went into the arm, abdomen, or thigh.¹² This is why some drugs allow flexible site choice while others specify the abdomen in their labeling. If your medication instructions call for a particular site, it is likely because clinical data showed a meaningful difference for that specific drug.

How the drug itself behaves chemically also matters. More water-soluble compounds tend to absorb completely regardless of site, while more fat-soluble ones can show erratic and sometimes incomplete absorption depending on injection depth, drug concentration, and the solution they are dissolved in.¹³

Heat, Blood Flow, and the Bottleneck That Is Not What You Think

A common assumption is that warming the injection site speeds up absorption because it increases blood flow. Applying local heat does increase tissue perfusion, and for many subcutaneously administered drugs, external heating does lead to higher blood concentrations.¹³ But the picture is more nuanced than “more blood flow equals faster absorption.”

A carefully designed study of insulin absorption measured what happened when local heat boosted tissue blood flow by roughly 145%. Despite that large increase in perfusion, there was no correlation between blood flow at the site and how fast insulin was absorbed. The researchers concluded that for high-concentration short-acting insulin, the rate-limiting step is not blood flow at all. It is the time needed for insulin molecules to break apart from their stored cluster form into individual units small enough to cross into capillaries.¹⁴ Insulin is formulated as clusters of six molecules, called hexamers, and it cannot be absorbed until these dissociate into smaller forms. Different rapid-acting insulin analogues do this at very different speeds. One analogue (glulisine) breaks apart in under ten seconds upon dilution, while others (lispro and aspart) can take anywhere from seconds to an hour depending on the preservatives in the formulation.¹⁵ The physical state of the molecule in its vial is, for insulin at least, more important than the blood flow at the injection site.¹⁶

This is a good example of why the subcutaneous route is trickier than it looks. The depot is not a passive holding tank. Chemical reactions inside it, interactions between the drug and the tissue’s own proteins, and the local fluid dynamics all shape what the bloodstream ultimately receives.

Speeding Things Up With an Enzyme

One approach to accelerating subcutaneous absorption targets the tissue itself rather than the drug. Hyaluronic acid is a gel-like substance in the connective tissue between cells, and it acts as a natural barrier to the spread of injected fluid. Recombinant human hyaluronidase (rHuPH20) is an enzyme that temporarily breaks down this barrier, allowing the injected drug to disperse over a wider area and reach capillaries and lymphatic vessels faster.

When co-injected with rapid-acting insulin analogues in clinical studies, rHuPH20 roughly doubled insulin exposure during the first hour after injection, produced a higher and earlier peak, and cut the lingering tail of insulin action by about 45 minutes. It also reduced the variability that normally plagues insulin absorption, making repeat injections more consistent and narrowing differences across dose sizes.¹⁷ This technology is now used commercially in several biologic drugs where faster or higher absorption from the subcutaneous route is desirable.

When the Needle Goes Too Deep

A subcutaneous injection is meant to stay in the fat. If the needle penetrates through the fat and into the underlying muscle, the drug effectively becomes an intramuscular injection, which can change how quickly it is absorbed and how it behaves pharmacologically. The risk of this is not trivial. With the most commonly used insulin needle worldwide (8 mm), modeling based on ultrasound measurements of tissue thickness estimated a 25% chance of hitting muscle in the thigh and about 10% in the abdomen when the needle is inserted straight in without pinching the skin. Switching to a 4 mm needle dropped those risks dramatically, to roughly 1.6% in the thigh and 0.1% in the abdomen.¹⁸

In children, the subcutaneous layer is thinner, making this problem worse. A study in pediatric patients found that intramuscular risk with 15 mm needles reached 98% in the thigh, and even 5 mm needles carried risk up to 54% in boys without a skin fold. Raising a skin fold before injecting and using shorter needles both reduced the risk substantially.³ This is why injection technique guidance has shifted in recent years toward shorter needles for most patients.

Obesity creates the opposite concern. The subcutaneous layer can be so thick that even a standard needle may not reach its intended depth, and changes in fat tissue composition can alter how the drug is absorbed.¹⁹ In both extremes, the anatomy of the person shapes the journey of the drug as much as any property of the drug itself.

Backflow and Leakage

Not all of the injected fluid stays where you put it. After the needle is withdrawn, some liquid can leak back out through the puncture track, which clinicians call backflow. This is a real problem for drugs dosed precisely, like insulin, where even a small loss changes the effective dose.

Testing in pig skin showed that several factors influence how much leaks out. Thinner needles cause less leakage: a 32-gauge needle leaked less than a 31-gauge. Inserting the needle straight in at 90 degrees caused less leakage than angling it at 45 degrees, likely because the straight puncture creates a shorter channel for fluid to escape through. And waiting at least three seconds after the injection before pulling the needle out reduced leakage compared to withdrawing immediately.²⁰ A separate study confirmed that the needle’s outer diameter was the pivotal factor, with a very thin 34-gauge, 3 mm needle producing less backflow than wider alternatives.²¹

If you have ever noticed a drop of liquid on your skin after an injection, this is what happened. It does not mean the injection failed, but it does mean a small fraction of the dose did not make it into the tissue. Holding the needle in place for a few seconds after pressing the plunger is the simplest countermeasure.

What Happens When You Use the Same Spot Too Often

People who inject daily, particularly those managing diabetes, sometimes develop visible or palpable changes at their favorite injection sites. Repeated injections into the same area promote fat tissue thickening and scarring, a condition broadly called lipodystrophy. These altered tissue areas can trap insulin and release it unpredictably, creating what researchers describe as subcutaneous insulin depots. The result is delayed, blunted, and highly variable absorption that makes blood sugar control harder.²² Site rotation, where you systematically move each injection to a different spot within a region, exists specifically to prevent this tissue remodeling.

Microneedles and the Dermis Question

Most subcutaneous injections target the fat layer below the dermis. But newer delivery technologies, particularly hollow microneedle patches, are designed to deposit drug into the dermis itself, which is shallower and has a different capillary and lymphatic density. Simulation work modeling insulin delivery through microneedles found that the target skin layer dramatically changes how the drug moves through tissue. Insulin deposited in the dermis versus the deeper hypodermis showed different absorption kinetics and produced different plasma insulin profiles over time, because the blood and lymphatic supply differ between the two layers.²³ This is an active area of device development, and it underscores how much the answer to “where does the injection go” depends on not just depth in millimeters but which tissue type the drug encounters at that depth.

When the Immune System Notices

A single subcutaneous injection of a foreign protein typically absorbs within hours without any visible tissue reaction. But the immune system keeps track. Classic experiments in rabbits showed that after four repeated subcutaneous injections of horse serum, the injection site developed redness and soft swelling that resolved in a few days. By the fifth injection, the swelling was firmer and lasted nearly a week. By the sixth, the tissue showed obvious damage and white masses. By the seventh, the skin itself began to die.²⁴ This progressive immune reaction, known as the Arthus phenomenon, is an extreme demonstration of what can happen when the body is repeatedly sensitized to an injected substance. Modern biologic drugs are engineered to minimize this kind of immune recognition, but injection-site reactions remain one of the most common side effects reported with subcutaneous biologics, typically presenting as mild redness or swelling rather than anything approaching the severity seen in those early experiments.